Pathologically altered alpha-synuclein fibrillizes and forms Lewy bodies (LBs) and Lewy neurites in Parkinson's disease (PD) and related disorders referred to as synucleinopathies because alpha-synuclein inclusions are the predominant brain lesions in these diseases. However, similar lesions are abundant in a common subtype of sporadic Alzheimer's disease (AD) known as the LB variant of AD (LBVAD), as well as in familial AD and Down's syndrome, while LBs and Lewy neurites have been reported in some tauopathies such as progressive supranuclear palsy (PSP) and Guam amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC). Moreover, while glial cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA) are composed of fibrillized alpha-synuclein, aggregated tau predominates in a subset of GCIs. Thus, fibrillary deposits of alpha-synuclein, Abeta and tau co-occur in neurodegenerative diseases, and some cells harbor both alpha-synuclein and tau inclusions. Since we showed alpha-synuclein promotes tau fibrillization into homopolymeric filaments, we hypothesize that alpha-synuclein interacts with amyloidogenic tau and Abeta in synucleinopathies to induce their oligomerization and/or fibrillization. Indeed, oligomers of tau and Abeta could contribute to neurodegeneration in synucleinopathies before coalescing into morphologically detectable fibrillar inclusions. Thus, we now propose to test the hypothesis that pathological alpha-synuclein interacts with tau and Abeta to promote their oligomerization, fibrillization and accumulation in synucleinopathy brains while heat shock proteins may mitigate this. The elucidation of mechanisms underlying neurodegenerative brain amyloidoses involving alpha-synuclein, tau and Abeta is essential for the design of more effective therapeutic interventions for synucleinopathies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG009215-18
Application #
7417827
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
18
Fiscal Year
2007
Total Cost
$293,461
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2015) Pattern of extrapyramidal signs in Alzheimer's disease. J Neurol 262:2548-56
Paumier, Katrina L; Luk, Kelvin C; Manfredsson, Fredric P et al. (2015) Intrastriatal injection of pre-formed mouse ?-synuclein fibrils into rats triggers ?-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 82:185-199
Kalia, Lorraine V; Lang, Anthony E; Hazrati, Lili-Naz et al. (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100-5
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12
Motsinger-Reif, Alison A; Zhu, Hongjie; Kling, Mitchel A et al. (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun 1:28
Arnold, Steven E; Toledo, Jon B; Appleby, Dina H et al. (2013) Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol 521:4339-55
Kaddurah-Daouk, R; Zhu, H; Sharma, S et al. (2013) Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry 3:e244
Couthouis, Julien; Hart, Michael P; Erion, Renske et al. (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 21:2899-911
Hu, William T; Holtzman, David M; Fagan, Anne M et al. (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79:897-905
Chen-Plotkin, Alice S; Unger, Travis L; Gallagher, Michael D et al. (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32:11213-27

Showing the most recent 10 out of 208 publications